Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

V 710

Drug Profile

V 710

Alternative Names: 0657nI Staphylococcus aureus vaccine - Merck; S.aureus vaccine - Merck; Staphylococcus aureus vaccine - Merck; V-710

Latest Information Update: 10 Jun 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Intercell
  • Developer Merck & Co
  • Class Bacterial vaccines; Surface antigens
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Staphylococcal infections

Most Recent Events

  • 28 May 2013 Intercell has merged with Vivalis to form Valneva
  • 09 Jun 2011 Merck and Intercell terminate their phase II/III trial in Staphylococcal infections in USA, European Union, Asia and South America due to efficacy concerns (NCT00518687)
  • 18 Apr 2011 Merck and Intercell suspend their phase II/III trial in Staphylococcal infections in USA, European Union, Asia and South America (NCT00518687)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top